Ash Stevens, Inc. was founded in 1962 to provide chemical research for the government and later branched out into the private sector. Ash Stevens, Inc. company, a contract pharmaceutical manufacturer develops and manufactures active pharmaceutical ingredients (APIs) for other pharmaceutical companies. It also supports clinical drug trials and helps others navigate the FDA's regulatory maze. Its customers include the federal government and commercial pharmaceutical firms. The company's portfolio includes about a dozen FDA-approved drug components.

Insmed Incorporated Company was founded in 1999 and is headquartered in Richmond, Virginia. Insmed Incorporated, a development stage company, engages in the development of recombinant protein drug. The company's primary product includes IPLEX, a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions, as well as conducting a phase III enabling clinical trial for investigating IPLEX as a treatment for myotonic muscular dystrophy. Insmed also engages in various oncology programs, including INSM-18, an orally available small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of IGF-1 and human epidermal growth factor receptor; and rhIGFBP-3, which is in early clinical development stage for the treatment of breast, prostate, liver, ovarian, and colon cancers. The company also provides Expanded Access Program in Italy to offer IPLEX to physicians for use in their patients with amyotrophic lateral sclerosis. It has a license to Pharmacia AB's portfolio of regulatory filings pertaining to rhIGF; and an agreement with NAPO Pharmaceuticals that gives NAPO the right to develop, manufacture, and commercialize masoprocal products for various indications relating to diabetes, cardiac disease, vascular disease, metabolic disease, and syndrome X.

Innovative work in genetic testing is apparently spelled Innogenetics in any language. The biopharmaceutical company creates genetic, infectious disease, cancer, and neurological tests. Innogenetics' products include tests and genotyping profiles to identify conditions such as cystic fibrosis, HIV, hepatitis C and B, Alzheimer's disease, and human papillomavirus (HPV). In addition to testing, the company provides biological manufacturing services (producing virus strains and proteins) for pharmaceutical firms and research labs. The firm's products are sold through subsidiaries and distributors in about 90 countries. Belgium's Solvay took over control of Innogenetics in 2008.

Fertile minds at Merck Serono help people around the world combat infertility. One of the world's top biotechs, Merck Serono focuses on recombinant genetic engineering to develop drugs. The firm also manufactures and markets therapies for neurological, dermatological, metabolic, oncology, cardiovascular, and growth disorders. It is a leader in reproductive health, with flagship drug Gonal-F at the head of its infertility product line. Other key products include beta interferon drug Rebif for the treatment of multiple sclerosis (MS) and colorectal and head/neck cancer treatment Erbitux. The company is a subsidiary of German drugmaker Merck KGaA.

Protide Pharmaceuticals is pro-cell. The firm focuses on developing new technologies for cellular and transfusion therapies, including gene therapies, to treat cancer and genetic disorders and to improve cell transplantation and engineering. To fund its work, Protide sells nearly 20 products under the Celox Laboratories brand to its academic, drug, and diagnostic research clients around the world. These products include serum-free growth mediums and supplements, as well as solutions used to cryopreserve cells and tissues. ICN Pharmaceuticals has a non-exclusive global marketing agreement for certain products. Protide also has a private-label manufacturing deal with a division of Sigma-Aldrich.

Antigenics was founded in 1994 and is headquartered in Lexington, Massachusetts. Antigenics Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its products include Oncophage (vitespen), a patient-specific therapeutic cancer vaccine registered for use in the Russia Federation, as well as under review by the European Medicines Agency for the treatment of kidney cancer patients with earlier-stage disease. The company tested Oncophage in phase 3 clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and phase 1 and phase 2 clinical trials for various indications, as well as in phase 2 clinical trial for the treatment of recurrent glioma, a type of brain cancer. Its product candidate portfolio also includes QS-21 Stimulon adjuvant, which is used in various vaccines under development in trials for diseases, such as hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer's disease, malaria, and tuberculosis; AG-707, a therapeutic vaccine program for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for the treatment of solid malignancies and B-cell lymphomas. The company was formerly known as Antigenics L.L.C. and changed its name to Antigenics, Inc. in February 2000.

Dr. Reddy’s Laboratories Limited (Dr. Reddy’s) is a global pharmaceutical company. The Company operates in three segments: Pharmaceutical Services and Active Ingredients (PSAI), which includes active pharmaceutical ingredients and intermediaries, which are the principal ingredients for finished pharmaceutical products; Global Generics, which consists of finished pharmaceutical products ready for consumption by the patient, and Proprietary Products, which involves the discovery of new chemical entities for subsequent commercialization and out-licensing. Dr. Reddy’s is vertically integrated and uses its pharmaceutical ingredients and intermediates in its own finished dosage products. The Company conducts basic research mainly in the areas of metabolic disorders, cardiovascular diseases and bacterial infection. On July 30, 2008, it acquired 85.69% interest in Perlecan Pharma Private Limited (Perlecan Pharma). Subsequently Perlecan Pharma became a wholly owned subsidiary of the Company.

Targacept, Inc. was founded in 1997 and is based in Winston-Salem, North Carolina. Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of neuronal nicotinic receptors (NNR) Therapeutics for the treatment of multiple diseases and disorders of the central nervous system. The Company has clinical-stage product candidates for target indications in three therapeutic areas, which includes cognitive impairment, depression and anxiety, and pain. It also has preclinical programs focused in smoking cessation, addiction, obesity, pain, Parkinson’s disease and inflammation. The Company has collaboration with AstraZeneca and an alliance with GlaxoSmithKline. The drug discovery activities utilize computer-based molecular design methodologies and biological data for a library of compounds developed and collected over more than 20 years. The technologies are referred to as Pentad. The Company use Pentad to design or optimize AZD3480 (TC-1734), TC-5619, TC-2216 and TC-6499.

EpiCept has made leukemia remission its entire mission. Its lead cancer drug candidate, Ceplene, is designed for use in adult patients who have had a complete remission from acute myeloid leukemia, but who are still at risk for relapse. It has been approved for use, along with interleukin-2, as a remission maintenance therapy in the EU, and it is awaiting approval in the US. The company's pipeline includes other cancer candidates, as well as topical analgesics for both acute and chronic pain. However, EpiCept has put all drug-discovery work on the back burner to focus on bringing Ceplene to market.

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen® and Oragens®.Alferon N Injection® is the company's registered trademark for its injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection. Alferon N Injection® (interferon alfa-n3 human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Alferon LDO® (Low Dose Oral) is a new experimental drug delivery platform for the Company’s highly purified, natural source alpha interferon.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.